When Patents End at Borders: The Semaglutide Export Battle
Think of a blockbuster drug as a locked house. The patent is the key. But here’s the twist every country has its own lock.
Semaglutide, the molecule behind Ozempic, is protected by Novo Nordisk in many markets, including India. A recent Delhi High Court order allowed Dr Reddy’s to manufacture semaglutide in India and export it to countries where Novo does not hold a valid patent. Selling it inside India, however, remains prohibited until March 2026. Novo Nordisk has now appealed this ruling.
This case highlights a critical reality of global pharma. Patents are territorial. If protection doesn’t exist in a destination country, Indian manufacturers can legally produce and export the drug—even if the innovator still dominates other markets.
For Indian pharma companies, this is not new. For decades, they have built scale by supplying regulated and semi-regulated markets once patent walls fall or don’t exist. Export-only permissions reduce legal risk while still unlocking manufacturing and formulation capabilities.
For innovators like Novo Nordisk, the concern is precedent. Even limited export rights can create competitive pressure on pricing and supply chains in global markets.
This is not about shortcuts. It is about how law, manufacturing strength, and global demand intersect. India’s pharma sector sits right at that junction.
Indian Nifty 500 stocks linked to this theme (learning context):
Dr Reddy’s Laboratories – complex generics, export-led growth
Sun Pharmaceutical Industries – specialty & global generics
Cipla